C5b-9 Antibody

(Synonyms: C5; C6; C7; C8; C9; Complement component 5; Complement component 6; Complement component 7; Complement component 8; Complement component 9; MAC; Membrane attack complex; TCC; Terminal complement complex.)
1 Cited Publications
Customer Review

Based on 1 publication(s) in Google Scholar

C5b-9 Antibody is a Rabbit-derived and non-conjugated IgG polyclonal antibody, targeting to C5b-9.

For research use only. We do not sell to patients.
  • Host:

    Rabbit

  • Isotype:

    IgG

  • Application:

    WB, IHC-P, IHC-F, ICC/IF

  • Reactivity :

    Human, Rat

  • Formulation:

    Supplied in 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol or 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.

  • Conjugation:
    Non-conjugated

Publications Citing Use of MedChemExpress (MCE) C5b-9 Antibody

More
1 Publications Citing Use of MCE C5b-9 Antibody (1)
IHC
  • IHC

Applications

Application
WB Info
WB: Western Blot
IHC-P Info
IHC-P: Immunohistochemistry-Paraffin
IHC-F Info
IHC-F: Immunohistochemistry-Frozen
ICC/IF Info
ICC/IF: Immunocytochemistry/
Immunofluorescence
Dilution Ratio 1:500-2000 1:100-500 1:100-500 1:100-500

Product Details

Description

C5b-9 Antibody is a Rabbit-derived and non-conjugated IgG polyclonal antibody, targeting to C5b-9.

  • Host Rabbit
  • Clonality Polyclonal
  • Species Reactivity
    Human, Rat Predicted Reactivity: Mouse
    Info
    Note: The predicted reactivity is for reference only and should not be considered a guarantee of product performance.
  • Observed Molecular Weight
    Observed band size: 72 kDa Info
    Note: Due to possible protein modifications or aggregation, the molecular weight should be confirmed by actual measurement, and the predicted value is for reference only.
  • Calculated Molecular Weight Predicted band size: 72 kDa
Immunogen

Purified Human SC5b-9 Complex

Sensitivity

Endogenous

Purification

affinity purified

Conjugation

Non-conjugated

Modification

Unmodified

Isotype

IgG

RRID

AB_3103092

Product Properties

  • Appearance

    Solution

  • Formulation

    Supplied in 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol or 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.

  • Concentration

    Batch-dependent, Please check the COA for the concentration of each lot. Check Lot Concentration

  • Storage & Stability

    Stored at -20°C for 1 year. Avoid repeated freeze / thaw cycles.

  • Shipping

    Shipping with blue ice.

Verification Images

  • Experimental Validation Results for C5b-9 Antibody
    Western blot analysis of extracts from M-Liver using C5b-9 antibody. Proteins were transferred to a PVDF membrane and blocked with 5% nonfat powdered milk in PBST for 2 hour at room temperature. The primary antibody (1/2000) and Loading control antibody (GAPDH, 1/3000) was diluted with 5% nonfat powdered milk in PBST at 4°C overnight. Goat Anti-Rabbit IgG-HRP Secondary Antibody (1/8,000) was incubated for 45min at room temperature.
  • Experimental Validation Results for C5b-9 Antibody
    Immunohistochemical analysis of paraffin-embedded human oral cancer tissue using C5b-9 Antibody (HY-P81185, 1/500). The section was pretreated using heat mediated antigen retrieval with sodium citrate buffer (pH 6.0) for 8 minutes. The tissues were blocked with quick block buffer for 0.5 hours at room temperature, washed with PBS and PBST, and then incubated with the primary antibody overnight at 4℃. The detection was performed using an HRP conjugated compact polymer system. DAB was used as the chromogen. Tissues were counterstained with hematoxylin and mounted with DPX.
  • Experimental Validation Results for C5b-9 Antibody
    Immunohistochemical analysis of paraffin-embedded human liver cancer tissue using C5b-9 Antibody (HY-P81185, 1/500). The section was pretreated using heat mediated antigen retrieval with sodium citrate buffer (pH 6.0) for 8 minutes. The tissues were blocked with quick block buffer for 0.5 hours at room temperature, washed with PBS and PBST, and then incubated with the primary antibody overnight at 4℃. The detection was performed using an HRP conjugated compact polymer system. DAB was used as the chromogen. Tissues were counterstained with hematoxylin and mounted with DPX.
  • Experimental Validation Results for C5b-9 Antibody
    Immunohistochemical analysis of paraffin-embedded human thyroid cancer tissue using C5b-9 Antibody (HY-P81185, 1/500). The section was pretreated using heat mediated antigen retrieval with sodium citrate buffer (pH 6.0) for 8 minutes. The tissues were blocked with quick block buffer for 0.5 hours at room temperature, washed with PBS and PBST, and then incubated with the primary antibody overnight at 4℃. The detection was performed using an HRP conjugated compact polymer system. DAB was used as the chromogen. Tissues were counterstained with hematoxylin and mounted with DPX.
  • Experimental Validation Results for C5b-9 Antibody
    Immunohistochemical analysis of paraffin-embedded human urothelial cancer tissue using C5b-9 Antibody (HY-P81185, 1/500). The section was pretreated using heat mediated antigen retrieval with sodium citrate buffer (pH 6.0) for 8 minutes. The tissues were blocked with quick block buffer for 0.5 hours at room temperature, washed with PBS and PBST, and then incubated with the primary antibody overnight at 4℃. The detection was performed using an HRP conjugated compact polymer system. DAB was used as the chromogen. Tissues were counterstained with hematoxylin and mounted with DPX.
  • Experimental Validation Results for C5b-9 Antibody
    Immunohistochemical analysis of paraffin-embedded human colon cancer tissue using C5b-9 Antibody (HY-P81185, 1/500). The section was pretreated using heat mediated antigen retrieval with sodium citrate buffer (pH 6.0) for 8 minutes. The tissues were blocked with quick block buffer for 0.5 hours at room temperature, washed with PBS and PBST, and then incubated with the primary antibody overnight at 4℃. The detection was performed using an HRP conjugated compact polymer system. DAB was used as the chromogen. Tissues were counterstained with hematoxylin and mounted with DPX.
  • Experimental Validation Results for C5b-9 Antibody
    Immunohistochemical analysis of paraffin-embedded human rectum cancer tissue using C5b-9 Antibody (HY-P81185, 1/500). The section was pretreated using heat mediated antigen retrieval with sodium citrate buffer (pH 6.0) for 8 minutes. The tissues were blocked with quick block buffer for 0.5 hours at room temperature, washed with PBS and PBST, and then incubated with the primary antibody overnight at 4℃. The detection was performed using an HRP conjugated compact polymer system. DAB was used as the chromogen. Tissues were counterstained with hematoxylin and mounted with DPX.
  • Experimental Validation Results for C5b-9 Antibody
    Immunocytochemistry analysis of Hela cells labeling C5b-9 with C5b-9 Antibody (HY-P81185) at 1/100 dilution. Cells were fixed in 4% paraformaldehyde for 15 minutes at room temperature, permeabilized with 0.1% Triton X-100 in PBS for 15 minutes at room temperature, then blocked with quick block buffer for 10 minutes at room temperature. Cells were then incubated with C5b-9 Antibody (HY-P81185) at 1/100 dilution in quick block buffer overnight at 4 ℃. AF488-conjugated Goat Anti-Rabbit IgG H&L (HY-P8002, Green) was used as the secondary antibody at 1/1,000 dilution. PBS instead of the primary antibody was used as the secondary antibody only control. The Nuclear counterstain was DAPI (Blue).
  • Experimental Validation Results for C5b-9 Antibody
    Immunocytochemistry analysis of Hela cells labeling C5b-9 with C5b-9 Antibody (HY-P81185) at 1/300 dilution. Cells were fixed in 4% paraformaldehyde for 15 minutes at room temperature, permeabilized with 0.1% Triton X-100 in PBS for 15 minutes at room temperature, then blocked with quick block buffer for 10 minutes at room temperature. Cells were then incubated with C5b-9 Antibody (HY-P81185) at 1/300 dilution in quick block buffer overnight at 4 ℃. AF488-conjugated Goat Anti-Rabbit IgG H&L (HY-P8002, Green) was used as the secondary antibody at 1/1,000 dilution. PBS instead of the primary antibody was used as the secondary antibody only control. The Nuclear counterstain was DAPI (Blue).

Background

  • Function

    C5b-9 is a Pore-forming component of the membrane attack complex (MAC), a multiprotein complex activated by the complement cascade, which inserts into a target cell membrane and forms a pore, leading to target cell membrane rupture and cell lysis. The MAC is initiated by proteolytic cleavage of C5 into complement C5b in response to the classical, alternative, lectin and GZMK complement pathways. The complement pathways consist in a cascade of proteins that leads to phagocytosis and breakdown of pathogens and signaling that strengthens the adaptive immune system. Constitutes the pore-forming subunit of the MAC complex: during MAC assembly, C9 associates with the C5b8 intermediate complex, and polymerizes to complete the pore[1][2][3][4][5][6][7][8][9][10][11].

  • Subcellular Localization

    Secreted; Target cell membrane; Multi-pass membrane protein

  • Expression


    Tissue_specificity:Plasma (at protein level)

  • Subunit

    Homooligomer; about 20 C9 chains oligomerize to give rise to a huge beta-barrel that forms a 100 Angstrom diameter pore in target membranes (PubMed:26841934, PubMed:30111885, PubMed:34752492). Component of the membrane attack complex (MAC), composed of complement C5b, C6, C7, C8A, C8B, C8G and multiple copies of the pore-forming subunit C9 (PubMed:22832194, PubMed:26841837, PubMed:26841934, PubMed:27052168, PubMed:30552328, PubMed:31061395, PubMed:34752492, PubMed:6177822)

  • SwissProt ID

    P01031 / P02748 / P07357 / P10643 / P13671

  • Gene ID
    727 [NCBI]
  • Synonyms

    C5; C6; C7; C8; C9; Complement component 5; Complement component 6; Complement component 7; Complement component 8; Complement component 9; MAC; Membrane attack complex; TCC; Terminal complement complex.

[1]. Hadders MA, et al. Assembly and regulation of the membrane attack complex based on structures of C5b6 and sC5b9. Cell Rep. 2012 Mar 29;1(3):200-7. [Content Brief]

[2]. Serna M, et al. Structural basis of complement membrane attack complex formation. Nat Commun. 2016 Feb 4;7:10587. [Content Brief]

[3]. Dudkina NV, et al. Structure of the poly-C9 component of the complement membrane attack complex. Nat Commun. 2016 Feb 4;7:10588. [Content Brief]

[4]. Sharp TH, et al. Heterogeneous MAC Initiator and Pore Structures in a Lipid Bilayer by Phase-Plate Cryo-electron Tomography. Cell Rep. 2016 Apr 5;15(1):1-8. [Content Brief]

[5]. Menny A, et al. CryoEM reveals how the complement membrane attack complex ruptures lipid bilayers. Nat Commun. 2018 Dec 14;9(1):5316. [Content Brief]

[6]. Podack ER, et al. Molecular organization of C9 within the membrane attack complex of complement. Induction of circular C9 polymerization by the C5b-8 assembly. J Exp Med. 1982 Jul 1;156(1):268-82. [Content Brief]

[7]. Lassiter HA, et al. The administration of complement component C9 enhances the survival of neonatal rats with Escherichia coli sepsis. Pediatr Res. 1997 Jul;42(1):128-36. [Content Brief]

[8]. Witzel-Schlömp K, et al. Heterogeneity in the genetic basis of human complement C9 deficiency. Immunogenetics. 1998 Jul;48(2):144-7. [Content Brief]

[9]. Spicer BA, et al. The first transmembrane region of complement component-9 acts as a brake on its self-assembly. Nat Commun. 2018 Aug 15;9(1):3266. [Content Brief]

[10]. Doorduijn DJ, et al. Polymerization of C9 enhances bacterial cell envelope damage and killing by membrane attack complex pores. PLoS Pathog. 2021 Nov;17(11):e1010051. [Content Brief]

[11]. DiScipio RG, et al. The architecture of complement component C9 and poly(C9). J Biol Chem. 1985 Nov 25;260(27):14802-9. [Content Brief]

View More

C5b-9 Antibody Related Classifications

MOQ
Minimum order quantity
100 mg

Get Quote In-stock

Other size
Get Quote
Please select quantity
Amount: USD 0.00